This study aims to develop the quantitative biomarker to establish the individualized strategy in stroke rehabilitation. Brain-derived neurotrophic factor (BDNF) acts on certain neurons of the central nervous system (CNS) helping to support the survival of existing neurons, and encourage the growth and differentiation of new neurons and synapses. BDNF in CNS can be assessed by analysing serum BDNF. The final objective of this study is to demonstrate a role of biomarker of BDNF in stroke rehabilitation to establish the individualized strategy.
Serum BDNF, proBDNF and MMP-9 in all participants will be measured before and after the comprehensive inpatient rehabilitation during subacute stroke phase. At 3 months after stroke onset, serum BDNF, proBDNF and MMP-9 will also be measured. In addition, motor impairment with Fugl-Meyer assessement will be assessed at same time points with serum analysis. We will compare potential serum biomarkers with motor impairment in stroke patients
Study Type
OBSERVATIONAL
Enrollment
150
comprehensive inpatient rehabilitation for 2 weeks
Samsung Medical Center
Seoul, South Korea
Serum BDNF
serum BDNF level
Time frame: At 2 weeks after the comprehensive inpatient rehabilitation
Serum proBDNF
Serum proBDNF level
Time frame: At 2 weeks after the comprehensive inpatient rehabilitation
MMP-9
MMP-9 level
Time frame: At 2 weeks after the comprehensive inpatient rehabilitation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.